FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143289308> ?p ?o ?g. }

• W2143289308 endingPage "674" @default.
• W2143289308 startingPage "669" @default.
• W2143289308 abstract "Purpose To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m 2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later. Results Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%). Conclusion This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel." @default.
• W2143289308 created "2016-06-24" @default.
• W2143289308 creator A5001591556 @default.
• W2143289308 creator A5001783218 @default.
• W2143289308 creator A5005231494 @default.
• W2143289308 creator A5005803748 @default.
• W2143289308 creator A5015774745 @default.
• W2143289308 creator A5019814247 @default.
• W2143289308 creator A5027462202 @default.
• W2143289308 creator A5042631007 @default.
• W2143289308 creator A5048477205 @default.
• W2143289308 creator A5050042851 @default.
• W2143289308 creator A5053359739 @default.
• W2143289308 creator A5057439948 @default.
• W2143289308 creator A5057559668 @default.
• W2143289308 creator A5068642720 @default.
• W2143289308 creator A5074479466 @default.
• W2143289308 creator A5087064759 @default.
• W2143289308 creator A5087541775 @default.
• W2143289308 creator A5088934171 @default.
• W2143289308 creator A5089256383 @default.
• W2143289308 date "2007-02-09" @default.
• W2143289308 modified "2023-10-10" @default.
• W2143289308 title "Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators" @default.
• W2143289308 cites W1915935221 @default.
• W2143289308 cites W1986527803 @default.
• W2143289308 cites W1996203783 @default.
• W2143289308 cites W2005718411 @default.
• W2143289308 cites W2006368250 @default.
• W2143289308 cites W2010086740 @default.
• W2143289308 cites W2013850508 @default.
• W2143289308 cites W2028322090 @default.
• W2143289308 cites W2033538744 @default.
• W2143289308 cites W2053571455 @default.
• W2143289308 cites W2056319477 @default.
• W2143289308 cites W2064536538 @default.
• W2143289308 cites W2080439368 @default.
• W2143289308 cites W2120292596 @default.
• W2143289308 cites W2128873194 @default.
• W2143289308 cites W2139248078 @default.
• W2143289308 cites W2153086817 @default.
• W2143289308 cites W2155679349 @default.
• W2143289308 cites W2155949904 @default.
• W2143289308 cites W2276223615 @default.
• W2143289308 cites W4241604062 @default.
• W2143289308 cites W4298312879 @default.
• W2143289308 cites W4323874020 @default.
• W2143289308 doi "https://doi.org/10.1200/jco.2006.06.8197" @default.
• W2143289308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17308271" @default.
• W2143289308 hasPublicationYear "2007" @default.
• W2143289308 type Work @default.
• W2143289308 sameAs 2143289308 @default.
• W2143289308 citedByCount "292" @default.
• W2143289308 countsByYear W21432893082012 @default.
• W2143289308 countsByYear W21432893082013 @default.
• W2143289308 countsByYear W21432893082014 @default.
• W2143289308 countsByYear W21432893082015 @default.
• W2143289308 countsByYear W21432893082016 @default.
• W2143289308 countsByYear W21432893082017 @default.
• W2143289308 countsByYear W21432893082018 @default.
• W2143289308 countsByYear W21432893082019 @default.
• W2143289308 countsByYear W21432893082020 @default.
• W2143289308 countsByYear W21432893082021 @default.
• W2143289308 countsByYear W21432893082022 @default.
• W2143289308 countsByYear W21432893082023 @default.
• W2143289308 crossrefType "journal-article" @default.
• W2143289308 hasAuthorship W2143289308A5001591556 @default.
• W2143289308 hasAuthorship W2143289308A5001783218 @default.
• W2143289308 hasAuthorship W2143289308A5005231494 @default.
• W2143289308 hasAuthorship W2143289308A5005803748 @default.
• W2143289308 hasAuthorship W2143289308A5015774745 @default.
• W2143289308 hasAuthorship W2143289308A5019814247 @default.
• W2143289308 hasAuthorship W2143289308A5027462202 @default.
• W2143289308 hasAuthorship W2143289308A5042631007 @default.
• W2143289308 hasAuthorship W2143289308A5048477205 @default.
• W2143289308 hasAuthorship W2143289308A5050042851 @default.
• W2143289308 hasAuthorship W2143289308A5053359739 @default.
• W2143289308 hasAuthorship W2143289308A5057439948 @default.
• W2143289308 hasAuthorship W2143289308A5057559668 @default.
• W2143289308 hasAuthorship W2143289308A5068642720 @default.
• W2143289308 hasAuthorship W2143289308A5074479466 @default.
• W2143289308 hasAuthorship W2143289308A5087064759 @default.
• W2143289308 hasAuthorship W2143289308A5087541775 @default.
• W2143289308 hasAuthorship W2143289308A5088934171 @default.
• W2143289308 hasAuthorship W2143289308A5089256383 @default.
• W2143289308 hasBestOaLocation W21432893081 @default.
• W2143289308 hasConcept C121608353 @default.
• W2143289308 hasConcept C126322002 @default.
• W2143289308 hasConcept C126894567 @default.
• W2143289308 hasConcept C141071460 @default.
• W2143289308 hasConcept C142724271 @default.
• W2143289308 hasConcept C168563851 @default.
• W2143289308 hasConcept C197934379 @default.
• W2143289308 hasConcept C203092338 @default.
• W2143289308 hasConcept C204787440 @default.
• W2143289308 hasConcept C207103383 @default.
• W2143289308 hasConcept C27081682 @default.
• W2143289308 hasConcept C2780192828 @default.

• next